CVS Health Corp vs Direxion Daily TSLA Bull 2X Shares — how do they compare? CVS Health Corp trades at $86.75 (market cap $112.29B), while Direxion Daily TSLA Bull 2X Shares trades at $10.43 (market cap $3.97B). The key difference: CVS Health Corp is far larger — about 28.3× Direxion Daily TSLA Bull 2X Shares's market cap, and CVS Health Corp pays a 3.03% dividend while Direxion Daily TSLA Bull 2X Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold CVS Health Corp for 83 Days and Direxion Daily TSLA Bull 2X Shares for 15 Days on average.
| CVS | TSLL | |
|---|---|---|
Market Cap | $112.29B | $3.97B |
Volume | 7,763,676 | 38,458,237 |
Sector | Health | Leveraged / Inverse |
52-Week High | $110.60 | $23.03 |
52-Week Low | $70.08 | $6.74 |
Typical Hold Time | 83 Days | 15 Days |
Enterprise Value | $174.64B | — |
Dividend Yield | 3.03% | — |
Signals from Pluang's Aura AI — not financial advice
CVS Health trades at $87.95, up 1.76% on the day, with a bullish technical signal and strong analyst support. Recent earnings beats in Q1 and Q2 2026, alongside steady revenue growth to $402.07B in 2025, highlight operational strength. The stock's valuation appears attractive with a P/E of 23.17 and P/S of 0.27, while a consensus price target of $111.20 suggests significant upside potential. Positive news includes Aetna's 2027 Medicare plan enhancements and a declared quarterly dividend.
The outlook for CVS remains positive, driven by earnings momentum and strategic initiatives in healthcare services. Key risks include reimbursement pressures and regulatory scrutiny, but Wall Street's 85% buy rating and institutional interest underscore confidence. Investors should weigh the stock's growth prospects against margin volatility and debt levels, with the current price offering a favorable entry point relative to targets.
TSLL (Direxion Daily TSLA Bull 2X Shares ETF) trades at $10.56, up 4.04% today, with a neutral technical signal overall despite bullish moving averages. The leveraged ETF amplifies Tesla's daily returns, with recent momentum driven by Tesla's Cybercab event anticipation. Key support sits at $10 with resistance at $11, while RSI indicators show mixed signals between short-term overbought conditions and neutral medium-term momentum.
As a leveraged ETF tracking Tesla, TSLL offers amplified exposure but carries significant volatility risks from daily rebalancing effects. The fund's performance remains entirely dependent on Tesla's stock movements, with recent news highlighting both opportunity from Tesla events and the structural risks of holding leveraged products long-term during volatile periods.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Following its acquisition of Aetna in late 2018, CVS Health now provides an even more integrated healthcare-services offering for its members. Legacy CVS combined both the largest pharmacy benefit manager, processing over 2 billion adjusted claims annually, and a sizable pharmacy operation, including nearly 10,000 retail pharmacy locations primarily in the U.S. Adding a managed-care organization with 24 million medical members gives the company a strong position in the insurance industry and should help CVS better control overall healthcare costs for its clients.
Read more on CVS →TSLL provides 200% of the daily performance of Tesla, Inc. (TSLA). It uses swaps and financial derivatives to achieve its 2x leverage, making it a high-volatility tool for tactical trading rather than long-term investment due to daily resets.
Read more on TSLL →